BRISTOL-MYERS SQUIBB CO (BMY)       80.28  +1.25 (+1.58%)

80.28  +1.25 (+1.58%)

US1101221083 - Common Stock - After market: 80.1 -0.18 (-0.22%)

BRISTOL-MYERS SQUIBB CO80.28

NYSE:BMY (11/30/2022, 3:34:53 PM)+1.25 (+1.58%)

After market: 80.1 -0.18 (-0.22%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 10-25 2022-10-25/amc Earnings (Next) 02-02 2023-02-02
Ins Owners 0.05% Inst Owners 77.24%
Market Cap 170.69B Shares 2.13B
PE 10.28 Fwd PE 9.97
Dividend Yield 2.79% Analysts 74.81
IPO 07-05 1929-07-05

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMY Daily chart

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. The company also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Company Info

BRISTOL-MYERS SQUIBB CO

430 E. 29Th Street, 14 Floor

New York City NEW YORK 10016

P: 12125464000.0

CEO: Giovanni Caforio

Employees: 32200

Website: https://www.bms.com/

BMY News

News Image7 hours ago - The Motley FoolAre Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?

Tech layoffs are in the news, but life sciences companies seem to be doing better.

News Image9 hours ago - The Motley Fool2 Massive Companies That Have Doubled Their Sales in 5 Years

Mergers and acquisitions have played a big part in the growth of these businesses.

News Imagea day ago - The Motley FoolAlexandria Real Estate Stock: Bull vs. Bear

Is Alexandria Real Estate worth the price?

News Image4 days ago - The Motley Fool3 Dividend Stocks to Hold Forever

These businesses -- and dividends -- are built to last.

News Image6 days ago - The Motley FoolIs Now the Time for Income Investors to Buy This Big Pharma Stock?

This drugmaker is among the most dominant pharmaceutical companies in the world.

News Image7 days ago - Investor's Business DailyMirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle

There are reportedly numerous companies in the mix and they're all awaiting data next month.

BMY Twits

Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example